Speaker Bios

Jack M. Anthony, *Founder, BioMentorz*

Jack M. Anthony, founder of BioMentorz, has a wealth of experience from over 37 years in healthcare. He is currently the CEO of Fibralign and formerly the CEO of Osprey Pharmaceuticals USA and CEO of Pharmix (now Numerate) and served as a member of the Board of Directors of Vaxgen, a public US company. Prior to his CEO roles Jack focused for 15+ years on biotech business development and marketing at a variety of biotech companies. Jack was Senior Vice President of Business Development at Saegis Pharmaceuticals (now at Lundbeck). He was a key player in the buyout of Tularik by Amgen where he led the Business and Commercial Group. In the fifteen years prior to Tularik he was the senior executive business development officer at FibroGen, Inc., Cell Therapeutics, Inc., Inhale, Applied Immune Sciences (now at sanofi-aventis) and General Manager of ExViT, the AIS subsidiary focused on the delivery of ex-vivo cell therapies. Jack began his life sciences career at Baxter Healthcare Corporation and for close to seventeen years held various sales, marketing and general management positions in the U.S. and internationally. He departed Baxter as a Vice President of the Blood Therapy Group. Prior to Baxter Jack cut his teeth selling at Olivetti and Proctor and Gamble. Jack has a BS in zoology from Allegheny College and served as a Navy Officer for five years. Jack was the Frank Barnes Mentor of the Year in 2004 of the Licensing Executives Society of the US/Canada.

John C. Balzano, *Special Counsel, Covington & Burling LLP*

John Balzano is a special counsel in the Food and Drug Practice Group at the law firm of Covington and Burling, LLP. He advises companies and industry associations on a variety of China-related regulatory compliance and market approval strategy matters, as well as regulatory advocacy and policy issues in China relating to drugs and biologics, medical devices, cosmetics and food. He also advises on a range of food and drug matters in the US. Prior to joining Covington, he was a senior fellow at the China Law Center of Yale Law School, where he worked with officials from Chinese regulatory agencies on general administrative law and food and drug law legislation projects. He speaks and reads Mandarin and Japanese.

Han S. Bang, *Managing Director, BETACHEM, INC.*

Han Bang joined BETACHEM, INC., a New Jersey based import & marketing company of drug substances and drug products. He has directed pharmaceutical, biotech and API initiatives, and held senior level jobs related to regulatory affairs and intellectual property. Over the years, he has participated in business development activities between US and Korean companies.

Most recently, he was US Representative of JW HOLDINGS, Korea and JW THERICAC PHARMACEUTICALS, Seattle. Prior to this, he was EVP, at DASAN MEDICHEM USA, NJ, and has also served the company as director, Scientific Division, K-GMP, bulk-GMP plant. Prior to this, Bang was director, marketing and business development for LIFECORD, Korea; and director of the Cell Therapy Center at AJOU MEDICAL UNIVERSITY. He started his career in the pharmaceutical industry in 1988 at YUHAN CORP and LG LIFE SCIENCE.

Han holds a BS in Business Administration and an MS from SOGANG UNIVERSITY, Korea. He is credited with multiple presentations, posters and publications.

Joshua Berlin, *Executive Director & Editor of New Ventures, BioCentury Publications Inc.*

Mr. Berlin develops editorial and business opportunities for BioCentury Publications Inc. with a particular focus on Asia and emerging markets. BioCentury is a leading provider of analysis and data on strategic issues essential to the formation, development and sustainability of life science ventures. Prior to joining BioCentury in May 2014, Josh for seven years created and led the emerging markets group for Elsevier Business Intelligence, providing business and regulatory intelligence on leading biopharma growth markets, including China, India and Japan. In this role he was responsible for developing PharmAsia News and the annual PharmAsia Summit, and served as strategy, editorial and business development lead for EBI in Asia and emerging markets. He serves on the editorial board for the World Korea Medical Journal and the agenda committee for the New York Health Forum. Mr. Berlin also comments on the industry via his Twitter handle @BioPharmaJosh.

Speaker Bios

Ben Bonifant, *Partner, Triangle Insights*

Ben Bonifant is an experienced consultant to leaders of global pharmaceutical and biotechnology organizations, and to decision makers of large private equity funds. Ben has been a management consultant for more than twenty years. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals.

Recent by-lined articles have appeared in Pharmaceutical Executive, InVivo, Nature Biotech, RPM Report, and Scrip. In addition, Ben's case studies on the pharmaceutical industry have been used in graduate business programs.

Ben is a member of the Life Sciences Executive Committee of the Licensing Executive Society. He has also been a member of the program committee for the BIO International Convention. Prior to the founding of Triangle Insights Group, Ben was the leader of the Business Development Practice at Campbell Alliance and a partner in the Strategy practice at Oliver Wyman (formerly Mercer Management Consulting/Strategic Planning Associates).

Ben has been a guest lecturer at Duke's Fuqua School of Business, the Indiana University Kelley School of Business, and industry conferences in the US, Europe, and Canada. Ben earned an M.B.A. from the Stanford Graduate School of Business and a B.S. from Duke University.

Pey Ni Chan, *Managing Director, CMIC Asia-Pacific, Pte. Ltd.*

Pey Ni Chan is the Managing Director of CMIC Asia-Pacific with headquarters in Singapore. She received her Master of Healthcare Organization Management and Bachelor of Public Health from the National Taiwan University, Taipei, Taiwan. She started her career in Asia regional private healthcare groups to spearhead new healthcare facilities start-up and business operations, followed by 15 years of experience working in the clinical research industry. She has been involved in a variety of senior management roles ranged from new company start-ups, strategic business development, clinical operations, project management, regulatory affairs to product planning and registration.

Helen Chen, *Director and Partner, Head of China Life Sciences, L.E.K. Consulting*

Helen Chen is a director and partner of L.E.K. Consulting based in Shanghai. She is the co-head of the China office and a member of L.E.K.'s Global Leadership Team, the firm's governing committee. Helen has over 20 years of consulting and industry experience in the US and Asia, and has resided in China since 2000.

Helen is the head of L.E.K.'s China life sciences practice, with extensive case work and industry experience covering the full bio/pharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. She is on the Editorial Board of PharmAsia and on the Advisory Committee for BIO China. Helen is a sought after speaker and author on the opportunities and issues in the China healthcare and life sciences.

Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997, and was honored by Who's Who Among American Women from 1993 to 1995.

Helen received her AB cum laude in applied mathematics from Harvard University.

Speaker Bios

Dohyun Cho, PhD, *President and CEO, W Medical Strategy Group*

Do Hyun Cho is currently the President and CEO of the consulting company, W Medical Strategy Group based in NJ, which provides judicious analysis, in-depth research and customized real-time advice for optimal business decisions to health industry entities including pharmaceuticals, medical devices, cosmetics and hospitals. Before being designated as the CEO of W Medical Strategy Group in February 2014, Do Hyun was the Director General of the Korea Health Industry Development Institute (KHIDI) USA in New York, a specialized agency of the Ministry of Health of the Republic of Korea. As the Director General of KHIDI USA, he was in charge of all KHIDI's activities in the United States and Latin America for 5 years. Prior to becoming the head of KHIDI USA, he worked for KHIDI Headquarters in Seoul, Korea as a senior researcher. He is known as an expert in international affairs and global trade in the bio-health industry. He was actively involved in many activities in and out of the bio/pharma industry including serving as the Advisory Member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center; the Korean government delegate for APEC Life Science Innovation Forum; the Healthcare division representative for the Korea-US Business Council; a Steering Committee member for the Korean American Chamber of Commerce, New York Health Forum Secretary.

Currently, he is Chief Advisor to the President of the World Korean Medical Organization; Editorial Board member of the World Korean Medical Journal, and Advisory Board member for Trans-Pacific Health Sciences Dialogue. He is also a columnist at Daily Pharm News, a South Korean Bio/pharm industry newspaper. Dohyun received his BA from the School of Law at Korea University in Seoul, Korea and graduated with an MA and a PhD in Health Sociology also from Korea University. Do Hyun completed a certified program from the US Food and Drug Administration and completed a fellowship with the University of Hertfordshire, UK. His awards include the 2011 Achievement Award of Korea's Ministry of Strategy and Finance.

Dr. Peter B. Corr, *Co-Founder and Managing General Partner of Auven Therapeutics*

Dr. Peter B. Corr is Co-Founder and Managing General Partner of Auven Therapeutics Management LLLP. Dr. Corr retired from Pfizer Inc in December 2006 where he was Senior Vice President for Science and Technology. In 2002 and 2003, he also headed worldwide pharmaceutical research and development for Pfizer.

Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development; and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.

Dr. Corr, who received his doctorate from Georgetown University School of Medicine, spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. When he left Washington University, Dr. Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts.

Dr. Corr is the recipient of numerous awards, including membership in the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health. He received the Washington University School of Medicine Teacher of the Year Award on several occasions and, in 1990, the Washington University Distinguished Faculty Award. In 2004, Dr. Corr was named a William Pitt Fellow at Pembroke College, Cambridge University, Cambridge, U.K.

Yuan-Hua Ding, *Executive Director, Head of External R&D Innovation-Asia Pacific, Pfizer*

Dr. Yuan-Hua Ding is an Executive Director and Head of Pfizer External R&D Innovation (ERDI) – Asia/Pacific, Pfizer Worldwide Research & Development (WRD). He is also a member of the ERDI senior leadership team. In this capacity, he partners with colleagues in ERDI and Pfizer Business Development Group to evaluate technologies and assets from Asia Pacific academic, biotech & pharma laboratories; seek opportunities to incubate early biotech companies, build and manage a research network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks. He liaises with therapeutic area and technology research unit leaderships in accessing the sciences, technologies and products needed to support Pfizer's mission in Asia.

Speaker Bios

Iain Dukes, MA, DPhil, *SVP, Business Development & Licensing Merck Research Laboratories*

Dr. Dukes joined Merck in 2013 and oversees all licensing deals at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances, and chairs the Merck Venture Research Fund. He has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, consultant to numerous biotech and venture capital organizations.

Iain was with Amgen prior to joining Merck since August 2010 as Vice President of External Research and Development. He led the External R&D department in identifying, assessing and transacting scientific external licensing opportunities, as well as potential opportunities for academic collaborations and platform technologies.

Previously, Iain was President and CEO of Essentialis Therapeutics, a small start-up company, and before that he served as Vice President, Scientific and Technology Licensing at GlaxoSmithKline, where he built a leading licensing organization. At an earlier point, he was the Head of the Ion Channel Drug Discovery Group, and later Head of Exploratory Development in Metabolic and Urogenital Diseases at GlaxoWellcome.

Iain pursued initial research training at the University of Leeds, UK, and received his D.Phil. degree from the University of Oxford where he also received a BA in Jurisprudence. He was a post-doctoral fellow in the Department of Physiology at the University of Pennsylvania, while simultaneously completing training at Gray's Inn, UK in anticipation of being called to the Bar.

Jay N. Fastow, JD, *Partner, Ballard Spahr*

Jay Fastow has successfully handled many important antitrust and financial services litigations. For example, he was lead trial and appellate counsel for plaintiffs in the recent ZF Meritor v. Eaton antitrust case, which settled for $500 million.

Mr. Fastow is a member of the advisory board of the Bloomberg BNA Antitrust and Trade Regulation Report, and a former adjunct lecturer in consumer finance law. He was named The Best Lawyers in America's 2013 New York City Litigation – Antitrust "Lawyer of the Year," and is regularly recognized in Chambers USA: America's Leading Lawyers for Business.

James Foley, PhD, *Managing Director, Aqua Partners LLC*

Over 30 years pharmaceutical industry experience spanning R&D, corporate development and licensing. Served as Head of business development and licensing of pharmaceuticals for Japan and Asia/Pacific regions at Bristol Myers Squibb, SmithKline Beecham and GlaxoSmithKline. Extensive longstanding relationships with Japanese pharmaceutical industry. Former member of Board of Directors of Sosei & Co. in Tokyo. Responsible for hundreds of millions of dollars worth of transactions in anti-infectives, inflammation, restenosis and cancer. PhD in Physiology and Pharmacology from Thomas Jefferson University and BA in Biology and Chemistry from Rutgers University.

Andrew Forman, *Global Life Sciences Transaction Advisory Services, EY*

Andrew Forman is EY's Global Life Sciences Transaction Advisory Services Resident.

He has 25 years of health care industry experience focused in biotechnology and specialty pharmaceuticals sectors including over 30 transactions involving over 50 companies in U.S., Europe, Eastern Europe, Russia, Latin America, Taiwan & China.

His 20 years of biotech/pharmaceutical industry experience includes sales, business development, strategic planning, M&A and analysis including 12 years on Wall Street covering the specialty pharmaceutical industry as equity research analyst.

Mr. Forman provides strategic advisory, business development and investor relations services for biotechnology, drug delivery and specialty pharmaceutical companies with focus on maximizing value for all stakeholders.

He was ranked #1 Pharmaceutical Analyst in 2006.

Has authored scores of industry reports, keynote speaker and commentator in media.

Speaker Bios

Les Funtleyder, *Portfolio Manager for Esquared asset Management and Director of Strategic Investments, OPKO Health*

Les Funtleyder is the healthcare Portfolio Manager for Esquared asset Management. He is also the Director of Strategic Investments for Opko Health, a multinational Pharmaceutical Company. He was a health care strategist and portfolio manager for of the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX). He joined Miller Tabak, after managing a health care portfolio for Provident Advisors, a hedge fund in Minneapolis, Minnesota. Before joining Provident, Les worked as a medical device analyst at UBS Warburg.

His industry experience includes directing clinical and business research at Innovative Health Solution, a joint venture of Merck and Wyeth; and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill), which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies.

John M. Gill, *Founder and Former Chief Executive Officer, TetraLogic Pharmaceuticals*

John Gill was a co-founder and Chief Executive Officer of Tetralogic Pharmaceuticals from October 2003 through August 2013. Prior to TetraLogic, John was a member of the board of directors and Chief Operating Officer of 3-Dimensional Pharmaceuticals, Inc., after having served 1979 until 2001 in several positions at SmithKline Beecham Corporation, now GlaxoSmithKline plc.

Glen Giovannetti, *Global Life Sciences Leader, EY*

Glen has over 29 years of experience with EY, the majority serving clients in the biotechnology and medical devices industries. He leads a team focused on understanding the evolving needs of clients in the life sciences industry, monitoring trends and business drivers, and networking and informing EY professionals serving the life sciences industry globally.

Glen has extensive experience in assisting clients with strategic transactions including equity and debt offerings, technology licensing and R&D collaborations, joint ventures and acquisitions.

He is a member of the Leadership Council of The Schwartz Center for Compassionate Care at Massachusetts General Hospital and serves on the Board of Trustees of Linfield College. He served as a member of the board of directors of the Biotechnology Industry Organization.

Glen graduated from Linfield College with a BA in Accounting.

Martyn D. Greenacre, MBA, *Former Chairman, BMP Sunstone*

Martyn D. Greenacre served as Chairman and a director of BMP Sunstone (formerly Beijing Med-Pharm) from 2004 to 2011. Mr. Greenacre has served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression and hospital decontamination since September 2001. Mr. Greenacre also serves as a director of Acusphere, Inc., Curis, Inc., and Neostem, Inc. From June 1997 to June 2001, Mr. Greenacre was Chief Executive Officer of DelsysPharmaceutical Corporation, a drug formulation company. From 1993 to 1997, Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to 1993 Mr. Greenacre served as Chairman Europe, SmithKline Beecham Pharmaceuticals.

Previously, Mr. Greenacre has served as a director of other companies including Cephalon, Inc. and OrchestraTherapeutics, Inc. Mr. Greenacre received an M.B.A. from Harvard Business School and a B.A. from Harvard College.

Speaker Bios

Kimberly Ha, *Senior Director, FTI Consulting*

Kimberly is currently Senior Director at FTI Consulting, Strategic Communications. Her focus area is Capital Markets, Life Sciences and Healthcare. She was previously Global Editor for BioPharm Insight, an independent business intelligence product launched by the Financial Times Group. She started her career as a financial journalist in Hong Kong specializing in healthcare M&A at Mergermarket and was the lead sector specialist before transferring to New York to build the business intelligence and editorial division for Biopharm Insight in 2007. Kimberly has been a sought-after panelist and moderator at major healthcare investor conferences and events, including the Prix Galien Awards, Biotech Showcase, Life Sciences Summit, and others. She is also a frequent guest speaker. In 2011, based on her extensive coverage of Alzheimer's disease, she was nominated by the Alzheimer's Association and was ultimately selected to be a National Press Foundation Fellow. She is also the recipient of the National Press Foundation and UN Foundation Global Vaccines Press Fellowship 2012, the Association of Health Care Journalists 2012 Fellowship Award (New York State Health Foundation), and the National Press Foundation's Fellowship on Cancer Issues 2012 in Washington, D.C. Kimberly is a Board Member for the Galien Foundation, and an advisor for OneMedPlace Forums in San Francisco and New York. She is also an expert for Startup Health, the first long-term growth academy to help healthcare entrepreneurs build sustainable businesses. Kimberly was also selected to be on the editorial board for the World Korean Medical Journal. She was recently appointed to the advisory board for the Trans-Pacific Health Sciences Dialogue based on her experience and knowledge of the healthcare sector in the Asia-Pacific region. She has a BA in Psychology from New York University. She is fluent in Cantonese, Shanghainese, and is proficient in Mandarin.

Ed Haug, *Partner, Frommer Lawrence & Haug LLP*

Ed Haug is a founding partner of Frommer Lawrence & Haug LLP and has served as the firm's Managing Partner since 2005. Mr. Haug is nationally recognized as a trial lawyer and consultant involving all aspects of intellectual property and competition law. He litigates in complex technical fields, including pharmaceuticals and biotechnology, semi-conductors and associated manufacturing equipment, e-commerce, automotive designs, GPS technology, and consumer electronics. He also counsels clients regularly in due diligence investigations.

Mr. Haug has extensive experience in bench and jury trials as well as appellate proceedings having appeared before the U.S. Supreme Court, Court of Appeals for the Federal Circuit and the Second Circuit. He has also represented clients involved in proceedings before the U.K. High Court, German Federal Supreme Court and the Tokyo High Court.

In addition to Mr. Haug's activities as a practicing attorney, he is a member of the Board and an Officer for the Federal Circuit Bar Association.

Mr. Haug is a frequent lecturer throughout the world regarding all aspects of trial advocacy in patent cases. Notably, Mr. Haug has lectured at the Practicing Law Institute, Joint Judicial Conferences in Tokyo (2011), Beijing (2012) and Seoul (2013), as well as the GRUR conference in Frankfurt, Germany.

Charles Hsu, PhD, *Founder & Managing Partner, Crosswave Management*

Charles has co-founded and/or invested in over 30 life sciences and healthcare companies, including Alpha Beta, AutoImmune, DNX, Axys Pharmaceuticals, KOSAN, Urocor, Lexicon Genetics, Telik, Biomatrix, RPI (later SiRNA) and Aviron, Inc., all of which went public on NASDAQ, and Plexxikon, which was acquired for over $900 million. His international involvements include Orgenics and D-Pharm (TASE: DPRM) in Israel; and Asia Renal Care, Mindray International (NYSE: MR), Eureka Pharmaceuticals, GenturaDx, LEAD Therapeutics, and China Biologic, all in Greater China. He was co-founder and initial CEO of LEAD. In addition, he advised certain investors in Wuxi Pharmatech's (NYSE:WX) pre-IPO round.

Charles is Founder and Manager of Crosswave, a China-focused venture management firm, and Senior Advisor to Mustang Ventures, based in Shanghai. He also serves on the Board of the Jacobs University Foundation, is an advisor to the Chinese American Biopharmaceutical Society (CABS) and ChinaBio LLC, and is a member of BayHelix. He holds an AB (Magna Cum Laude) in Biochemistry from Harvard and his PhD (Genetics) and MBA degrees from Stanford.

Speaker Bios

James Huang, *Managing Partner, Kleiner Perkins Caufield & Byers China*

James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm's life sciences practice. His main investment interests are innovation around China's growing healthcare markets and helping entrepreneurs build companies.

Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Judy Jarecki-Black, *Global Head of the Intellectual Property Department at Merial Limited, the Animal Health Division of Sanofi*

DR. JUDY JARECKI-BLACK is Global Head of the Intellectual Property Department at Merial Limited, the Animal Health Division of Sanofi. Dr. Jarecki-Black is admitted to the state bars of Georgia and South Carolina, and is admitted to practice before several federal courts including the United States Supreme Court. Since 2002, Dr. Black's department maintains and enforces Merial's global patent portfolio. Her department obtains patent protection, generates patentability and freedom-to-operate opinions, and conducts due diligence for a variety of licensing opportunities. Dr. Jarecki-Black is also responsible for global patent litigation and leads the trial team on all patent cases.

Tae-Wan Kim, PhD, *Associate Professor, Columbia University Medical School*

Dr. Kim is currently a tenured Associate Professor in the Department of Pathology and Cell Biology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University Medical Center. Dr. Kim is a translational neuroscientist who has more than 20 years of experience in Alzheimer's disease research. His research is focused on the identification of new therapeutic targets as well as first-in-class drug leads and candidates. He obtained his undergraduate degree from Yonsei University, Seoul, Korea, and received his Ph.D. in Neurobiology under the supervision of the late I. B. Black from Rutgers University. Following postdoctoral training with R. E. Tanzi as well as junior faculty appointments at the Massachusetts General Hospital and Harvard Medical School, he has consulted for many biopharmaceutical companies and venture capital companies. He has received a number of awards including Partners Investigator Nesson Award and Ruth Salta Junior Investigator Achievement Award.

Kiyoshi Kurokawa, MD, MACP, FRCP (London), *Academic Fellow, National Graduate Institute for Policy Studies; Chairman, Health and Global Policy Institute; Chair, Global Health Innovative Technology Fund*

A graduate of the University of Tokyo, professor of medicine at UCLA, University of Tokyo, Dean, Tokai University School of Medicine, President of the Science Council of Japan, Science Advisor to the Government of Japan; He served as an executive member of many national and international professional societies of his disciplines, Commissioner of WHO (2005-09), serve(d) as Board members of Alexandria Library (Egypt), A*STAR (Singapore), Khalifa University (Abu Dhabi), OIST (Okinawa), Advisory Board to the Prime Minister of Malaysia. He was the Chair of Fukushima Nuclear Accident Independent Investigation Commission by the National Diet of Japan (NAIIC; 2011.12-2012.7). He was appointed to be a member of the World Dementia Council by the UK Government in April, 2014. His website: http://www.kiyoshikurokawa.com/en

Speaker Bios

Wei Li, PhD, *Executive Partner - China, Fidelity Biosciences*



Prior to joining Fidelity in 2005, Dr. Li focused his effort on healthcare and life science investment opportunities at Baird Venture Partners, the venture capital arm of R.W.Baird. Prior to Baird, he led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a small-molecule therapeutic company based in Cambridge, MA. He also worked in strategic marketing at Serono International S.A., a biopharmaceutical company based in Geneva, Switzerland. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.

Wei received a BS, with distinction, in Chemical Physics from the University of Science and Technology of China, a PhD in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing. Dr. Li serves on the Board of Directors of TCT Medical and Innovent Biologics.

Anjiang (Vincent) Liu, *Managing Director, International Investment & Chief Representative, NY Office, FosunPharma Group*

Vincent joined the International Business Division of Shanghai Fosun Pharmaceutical Group in 2009 to lead the effort in executing Fosun Pharma's investment and M&A strategies in the North America region. Upon joining the company, he made a significant contribution to implementing Fosun Pharma's international strategies.

His achievements include helping the company to raise a $500 million private equity fund from overseas and setting up two JVs with large US and Canadian companies in China. Prior to joining Fosun Pharma, he served in several Chinese and U.S. startup companies as well as a healthcare focused PE/VC fund.

Vincent received his PhD degree in Molecular Biology from Drexel University and an MBA degree from the University of Rochester, NY.

Martina Molsbergen, *Chief Executive Officer, C14 Consulting Group*

Ms. Molsbergen has 20 years of business development, marketing, and entrepreneurial experience including 10 years of business development experience in biotherapeutics and antibodies. She has proven corporate development strategy and leadership experience within large and small company settings. Currently, she is the founder and CEO of C14 Consulting Group, LLC, which provides licensing and business development and strategy consulting to biotech and pharmaceutical companies and investors worldwide. She was the Vice President of Business Development (PER. C6 Licensing) at Crucell Holland BV. In this capacity she established the PER.C6 manufacturing technology platform for therapeutic antibodies and proteins, managed global business development team as well as the joint venture with DSM Biologics. She brought more than twenty new licensing opportunities.

Previously as the Vice President of Business Development, Ms. Molsbergen played a key role in establishing and building BioWa, Inc., a novel antibody engineering platform company as a subsidiary of a Japanese company Kyowa Hakko Kogyo (KHK). In three years of business activity, she successfully negotiated more than 15 deals valued at over $2.5 B in future milestone payments and royalties with leading antibody and biopharma companies. She participated with KHK to identify new investment opportunities, and strategic planning for internal product pipeline development. The efforts led to the creation of market value of BioWa to reach over $1B in three years. Ms. Molsbergen received two President's awards for her achievements.

In addition, Ms. Molsbergen has 12+ years of business development experience in small molecule pharmaceutical and manufacturing companies including Patheon, Circa Pharmaceuticals (Division of Watson Pharmaceuticals) and FMC Corporation. She has a BS in Chemical Engineering from Drexel University.

Ms. Molsbergen is founder and chair of the BD Connection, an informal group of BD professionals located on the east coast whose purpose is to create cohesiveness for life science deal-making in the region.

Speaker Bios

Robert Naismith, *Chairman/Cofounder, JUJAMA, Inc.*

Dr. Naismith serves Chairman of JUJAMA, Inc. a professional conference and community networking SAAS company. Until January 2008, **Naismith** served as Chairman and CEO of Life Science Analytics a company he founded and sold to London-based Datamonitor, Inc. His career to date has been one of serial entrepreneurship. He co-founded Pharmakon Research International, Inc., a major international preclinical contract research organization which was sold to DNX, Princeton.

In 1986 he founded Biofor, Inc., a biopharmaceutical company, and served as its President and CEO which was sold to Scherer Healthcare, Atlanta, GA. From 1996 to 1998, Dr. **Naismith** served as Chairman and Director of the MicroCap Fund and Managing Director of Healthcare at Bluestone Capital Partners, L.P. in New York, before founding Emedsecurities in 1998 a boutique investment bank serving the small-cap life-science industry. Emedsecurities was the predecessor to Life Science Analytics. He also cofounded with his daughter NND Biomedical Sciences, Hyderabad, India and served as Chairman and CEO

Dr. **Naismith** serves as a Director of Penn Security Bank and the Life Sciences Greenhouse of Central PA, a Trustee of the William Harvey Research Institute, (London, UK) and a member of the Kania School of Management's Advisory Board at the University of Scranton. In addition, Dr. **Naismith** is a founding member and served as Chairman of the Board of the Commonwealth Medical College a new and fully accredited allopathic medical school serving northeastern Pennsylvania. He was formerly an adjunct associate professor in the School of Medicine at Case Western Reserve University. adjunct Professor at the Pennsylvania University and the University of Scranton. He currently serves as an adjunct Professor at the Commonwealth Medical College, Dr. **Naismith** holds a Ph.D. in genetics from the Pennsylvania State University.

Keiko Oishi, *Senior Managing Director, CMIC Co., Ltd. (Japan)*

After earning her MS degree from the University of Tokyo, Keiko started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications), as a staff writer for Nikkei Biotech, the first Japanese newsletter specializing in biotechnology. She accumulated her biotechnology industry career through working at Genzyme Japan, Ltd., and Genentech, Ltd., a Japanese Branch of Genentech, Inc. in the U.S.

In 1996, Keiko joined CMIC Co., Ltd., the first CRO (Clinical Research Organization) in Japan, as Manager of the Strategy Development Department. In her current position as Senior Managing Director of CMIC HOLDINGS, Co., Ltd., she is responsible for International Business and Corporate Development, covering Japan, Korea, China, Singapore, Taiwan and other regions in Asia Pacific. She also serves on the company's Board of Directors.

Tomomi Okamoto, *Partner, Sophia Hill Venture Partners*

Tomomi is one of the best-known fund managers in the Japanese life-science industry. Her success rate is evidenced by a track record of leading syndicates and multiple finance projects. She started her career as a biochemical scientist in Toshiba R&D Center, and major corporate research institutes. Her fund manager career started in 2003 as CTO at a life-science boutique venture capital with $200MM USD total fund size. She served as a board member of her portfolio companies and multinational biotech firms including Quark Pharmaceuticals (CA, Israel), GNI (CA, JP, CN & UK) and supported their business development. She also has experience in strategic business consulting for new business planning at major Japanese corporations.

Since 2011, Tomomi has been instrumental in arranging life-science projects between Japan and Asia.

Tomomi is the life-science advisor of Commonwealth of Pennsylvania, Japan Office since 2004.

Speaker Bios

Grace L. Pan, *Partner, Orrick, Herrington & Sutcliffe LLP*

Grace L. Pan is an intellectual property counselor and litigator who is admitted to practice before the U.S. Patent and Trademark Office and the State Bars of New York, New Jersey and the District of Columbia. She is also admitted as a Gaikokuho Jimu Bengoshi, a registered foreign lawyer, in Japan and is a member of the Daini Bengoshi Kai, the Tokyo Bar Association.

Grace practices exclusively on matters before the U.S. Patent and Trademark Office and matters involving federal patent, federal copyright and federal trademark; she represents clients from the United States, Japan, Taiwan and China in the aforementioned areas of law. In addition, Grace is experienced in enforcing and defending patents, trademarks, trade dress before ITC and various District Courts within United States as well as the Courts of Appeals for the Federal Circuit in biotechnology, medical, organic chemistry, electronic, semiconductor, mechanical and related technical fields

Andrew L. Pecora, MD, *Chairman, TetraLogic Pharmaceuticals Corporation and Chief Visionary Officer, Neostem, Inc.*

Dr. Andrew Louis Pecora graduated from Seton Hall in 1979 with honors, receiving a BS in Biology. He completed medical school in 1983, receiving an MD from the University of Medicine and Dentistry of New Jersey with honors. In 1986, he completed an internship and residency in internal medicine at the New York Hospital-Cornell Cooperating Hospitals System. Dr. Pecora then moved on to Memorial Sloan-Kettering Cancer Center and completed a fellowship in hematology/oncology in 1989, after which he moved to Hackensack University Medical Center initially to serve as Director of the Adult Blood and Marrow Transplant Program. He was promoted in 2001 to serve as Chairman and Executive Administrative Director of the Cancer Center at Hackensack University Medical Center. In 2012 he was promoted to his current position of Vice President of Cancer Services and Chief Innovation Officer, Hackensack University Medical Center. Dr. Pecora also currently serves as President of Regional Cancer Care Associates. Dr. Pecora was promoted to Professor of Medicine, UMDNJ-New Jersey Medical School, in 2004 and in 2013 to Professor of Oncology and Medicine, Georgetown University.

Jurij Petrin, MD, *President and Chief Executive Officer, Pharmaceutical Regulatory Services, Inc.*

Jurij Petrin, MD, spent 10 years with Bristol-Myers Squibb in Europe and the US, first as Medical Director for Eastern Europe and later as Executive Director and finally Vice President for Intercontinental Regulatory Science. Before leaving BMS to start his own company in 2001, he was responsible for all Bristol-Myers Squibb's regulatory affairs in markets outside of the US and Europe. During his tenure, he organized and supervised international filings and approvals of new and supplemental submissions of (among others): paclitaxel (Taxol), stavudine (Zerit), cefprozil (Cefzil), cefepime (Maxipime), didanosine (Videx), pravastatin (Pravachol), irbesartan (Aprovel), butorphanol (Stadol), nefazodone (Serzone), fosinopril (Monopril), gatifloxacin (Tequin), and several others.

During his more than fourteen years of consulting, he worked on numerous projects for pharmaceutical and biotech companies, ranging from developing regulatory strategies for new drugs to providing worldwide regulatory support and services of all phases of drug development in various therapeutic areas. He was a consultant to PhRMA on Asian regulatory affairs, represented PhRMA at IFPMA in Geneva and served as a consultant for the ASEAN Harmonization effort to the Food and Drug Administration of Thailand. He occasionally teaches a postgraduate Masters course on Global Regulatory Affairs at Temple University in Philadelphia and was a faculty member of Eudipharm in Europe.

Speaker Bios

Terence G. Porter, PhD, *Vice President, Search and Evaluation, Takeda Pharmaceuticals International*

Terry Porter joined Takeda's Global Licensing & Business Development group in December 2011 as the Vice President of Search and Evaluation (S&E) team. In this role, Terry leads the team responsible for identifying and evaluating in-licensing opportunities across four of Takeda's therapeutic areas including Cardiovascular-Metabolic, CNS, Inflammation-Respiratory, and General Medicine.

Terry has over 25 years experience in the pharmaceutical and biotechnology industry. Before joining Takeda, he was the Managing Director at Aqua Partners for two years, which provided strategic advisory services to life science companies and investors. In addition, he had a long and successful career at GlaxoSmithKline (GSK), first as a research investigator, then as an integral member of GSK's global business development group where he held various leadership positions responsible, in partnership with key R&D stakeholder groups, for delivering upon GSK's global external science and technology strategy.

Starting out in Biotech at Seragen Inc., Terry has a broad knowledge across multiple aspects of business development including compound and technology assessment and licensing transactions, M&A and his licensing experience covers protein-based agents and conventional small molecules across multiple therapeutic areas.

Terry holds a BSc (Hons) in Biochemistry and a Ph.D. in Chemistry from the University of Manchester, UK.

Alan Seem, *Partner, Shearman & Sterling LLP*

Alan Seem is a corporate partner in the Palo Alto office of Shearman & Sterling LLP. His primary areas of focus are SEC-registered and Rule 144A/Regulation S securities offerings, mergers and acquisitions, venture capital and private equity investments and going-private transactions. His recent U.S. IPO experience includes those of Simcere Pharmaceutical, Nuokang Bio-pharmaceutical, Weibo, Renren, Acquity Group, New Oriental Education, Giant Interactive, BitAuto, TAL Education, Hanwha SolarOne, Lentuo International and SYSWIN. Alan also regularly advises companies and their boards of directors regarding corporate governance matters, including SEC/stock exchange compliance and disclosure-related matters. He is also a frequent speaker on a variety of corporate law-related subjects. Alan was the former head of Shearman & Sterling's Asia Capital Markets Group and the Beijing Office Managing Partner, having worked 16 years in the Hong Kong, Beijing and Shanghai offices, and remains active in S&S's China practice. Alan speaks and reads Mandarin Chinese fluently.

Richard L. Sherman, JD, *Senior Vice President, Strategic Transactions and General Counsel*

Mr. Sherman is Senior Vice President Strategic Transactions, Secretary and General Counsel of TetraLogic Pharmaceuticals Corporation (TLOG). He is also a principal in a private SBIC Investment fund, CIP Capital, L.P. and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia.

Mr. Sherman spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group.

Mr. Sherman has served on the Board of Directors of a number of public and private for-profit companies in the U.S. and Canada. He is currently a member of the Board of Directors of Hawaii Biotech, Inc. and of Immunomedics, Inc. (IMMU).

Speaker Bios

Scott A. Siegel, PhD, *Founder, Milestone Life Sciences, LLC*

Dr. Scott Siegel has a 25 year record of business and science achievements in biotech and pharma, including the execution of over 40 business development transactions and R&D development of 3 launched products, including as co-inventor of the blockbuster anti-TNF therapy Remicade®. His leadership experience ranges from start-ups to large multinationals, with a breadth of responsibilities spanning business, science, technologies and therapeutic areas. He founded and currently manages Milestone Life Sciences, a business development and strategic advisory firm to small biotech's and pharma. Dr. Siegel also serves as VP, Business Development for the newly formed non-profit Institute of Life Science Entrepreneurship, a NJ-based incubator, accelerator and aggregator, and he teaches a communications course in the Wharton School MBA program. Dr. Siegel earned his PhD in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral training in Pharmacology at the Yale University School of Medicine.

Loretta Smith, *Senior Counsel, Dupont Legal*

Loretta Smith is the patent attorney for several polymer businesses at DuPont and is admitted to practice before the U.S. Patent and Trademark Office, the State Bars of New York and New Jersey, and the U.S. Supreme Court. Loretta has an LL.M. in Comparative Law from Stockholm University. She counsels on invention development, patent acquisition, competitive intelligence; provides opinions and risk benefit analyses; and has done due diligence in licensing and merger deals in China and elsewhere.

Anthony Y. Sun, MD, *Partner, Aisling Capital*

Dr. Sun joined Fund I in 2002 and currently serves as a Partner. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. Dr. Sun currently serves as a director of Versartis (NASDAQ:VSAR) and a Board observer for Pharmaron Pharmaceuticals. Previously he served as a director of CeNeRx BioPharma, Dynova Laboratories, HerbalScience, MAP Pharmaceuticals and Paratek Pharmaceuticals. Dr. Sun received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his MBA from The Wharton School at the University of Pennsylvania and his BS in Electrical Engineering from Cornell University. In addition, he is Board Certified in Internal Medicine.

Mark Tang, PhD, MBA, *Founder and Chairman, GCA Therapeutics, Ltd.*

Since 2009, Dr. Tang has been director and Chairman of GCA Therapeutics, Ltd. Dr. Tang was a director of Tongli Pharmaceuticals (USA) Inc. (OTCBB: TGLP) since 2008. Dr. Tang has been the founder and CEO of World Tech Ventures, LLC, an international merchant banking and venture capital firm specialized in advising and investing in life sciences biotechnology since 2002. From 2004 to 2006, Dr. Tang was a director of Biotech Commercialization and an Instructor at Rutgers University Business School. From 1997 to 2000, Dr. Tang was a director and Co-founder of Aegisoft Corp. Dr. Tang holds a PhD degree in Biochemistry and Molecular Biology from University of California at Riverside and an MBA in Finance from Leonard N. Stern School of Business at New York University.

Theodore (Ted) J. Torphy, PhD, *Senior Vice President, Research & Development, BioMotiv*

Ted Torphy is Senior Vice President of R&D for BioMotiv, a for-profit therapeutics accelerator associated with The Harrington Project. In addition, he is Senior Advisor, R&D Strategy for the Cystic Fibrosis Foundation. Prior to joining BioMotiv Ted spent 12 years with Johnson & Johnson Pharmaceuticals. His roles included Global Head of External Innovation & Business Models for Discovery Sciences and Corporate Vice President and Head of Johnson & Johnson's Corporate Office of Science & Technology. In addition, he was Senior Vice President of Discovery and Preclinical Development at Centocor, the biopharmaceutical arm of Johnson & Johnson. Prior to joining Centocor, he spent 17 years with SmithKline Beecham, most recently as Vice President and Head of Biological Research for the Cardiovascular, Pulmonary, Renal and Metabolic Diseases therapeutic areas. Ted is the author of more than 120 journal articles, review articles, book chapters, and patents, and served on the editorial boards of numerous scientific journals. He holds a BS degree in Pharmacy from the University of Wisconsin and a PhD in Pharmacology and Toxicology from West Virginia University. He completed his postdoctoral training at the University of California, San Diego.

Speaker Bios

Joseph P. Vacca, *Sr. Vice President of Early Success Sharing Partnerships, WuXi AppTec Ltd.*

Dr. Joseph Vacca earned his BS in chemistry in 1977 from St. John Fisher College, Rochester, New York, and obtained his Ph.D. degree in Organic Chemistry under Professor Peter T. Lansbury Sr. at the State University of New York at Buffalo (Buffalo, New York). He joined Merck Research Laboratories in 1981 as a Senior Research Chemist and has contributed to several primary research projects including the discovery of HIV-1 and HCV protease inhibitors, and the discovery and development of HIV integrase inhibitors. His work on the HIV-1 protease project led to the discovery of Merck's HIV protease inhibitor CRIXIVAN™ (indinavir sulfate). He held several positions within Merck and retired in Nov. 2011. Dr. Vacca recently joined Wuxi Apptec Inc. as Sr. Vice President of Early Success Sharing Partnerships.

Dr. Vacca has over 100 publications and patents and is the holder of many awards including a Merck Directors Award (1998); PhRMA Discoverers Award (1999); Intellectual Property Owners "National Inventor of the year Award" (1997); European Inventor of the Year (non-EU nation) (2007); ACS "Award for Creative Invention" (1999); and was a named a Merck Research Laboratories Presidential Fellow in 2008. He was recently named to the American Chemical Society Medicinal Chemistry Hall of Fame (Aug. 2012) and was also named a "Hero of Chemistry" (along with the research team) for his role in the discovery and development of the HIV integrase inhibitor Isentress™.

Alex Waldron, *Vice President, Global Commercial Operations, Epirus Biopharmaceuticals*

Alex was formerly the Head of Commercial, Emerging Markets at Biogen Idec (NASDAQ: BIIB) where he developed the strategic and operational plans for geographic expansion and established a $100 M business in Asia Pacific. While at Biogen Idec he held multiple global commercial roles including lifecycle and portfolio planning, global brand management, early stage MS portfolio, and in-line marketing. Alex has more than 24 years of pharmaceutical and biotech experience and previously served in commercial leadership roles at Genzyme, Astra Zeneca, Pfizer and Bristol Meyers Squibb.

Wenyong Wang, PhD, *Managing Director, Merchant & Investment Banking, Burrill Securities*

Wenyong is currently a Managing Director of Merchant & Investment Banking at Burrill Securities. At Burrill, Wenyong initiates and executes deals for healthcare companies in capital raising, merger and acquisition, as well as joint venture, partnering and licensing transactions. Prior to joining Burrill in 2011, Wenyong accumulated his Investment Banking experiences with Boenning & Scattergood and Janney Montgomery Scott, two investment banking firms in Philadelphia. Wenyong has completed over thirty high profile transactions with an aggregated value of over five billion dollars. From 2001 to 2007, Wenyong gained extensive drug discovery and development expertise at GSK and delivered two drug candidates to clinical trials. Armed with a Ph.D. from Penn and an MBA degree, Wenyong has provided both strategic and financial advices to the healthcare industry for more than twenty years.

Speaker Bios

Harold R. Werner, *Managing Director, HealthCare Ventures*

Harold R. Werner is a General Partner and Founder of HealthCare Ventures LLC. HealthCare Ventures LLC manages one of the largest venture capital funds devoted exclusively to healthcare products and technologies. Healthcare Ventures has created over fifty pharmaceutical and related health care companies, including MedImmune (sold to Astra-Zeneca); Human Genome Sciences and Principia (sold to Glaxo SmithKline); PharmaVene, Inc. (now part of Shire Pharmaceuticals); Vicuron, Inc. and Fold-Rx (sold to Pfizer); GynoPharma, Inc. and 3-Dimensional Pharmaceuticals (sold to Johnson & Johnson); MediGene, Inc., PharmaGenics, Inc. and Novazyme Pharmaceuticals (sold to Genzyme/Sanofi); Genetic Therapy, Inc. and Oriel Therapeutics (sold to Sandoz/Novartis) and Aton, Inc. (sold to Merck)..

Mr. Werner has been involved over forty years in the planning, development, and financing of health care technology. Since co-founding HealthCare Ventures in 1985, he has served on the Boards of over forty public and private health care companies and has specialized in the formation of new high-science companies. Mr. Werner currently serves on the Board of Directors of Aciex, Inc.; Infacare Pharmaceutical Corporation; DecImmune Therapeutics, Inc.; and Stemgent, Inc. He also serves on the Board of Advisors of Ora, Inc., Beijing SynerCare Pharma Tech Co., Ltd. and EpiGen Pharmaceuticals, Inc.

Prior to the formation of HealthCare Ventures, Mr. Werner was Director of New Ventures for Johnson & Johnson Development Corporation, making outside investments and licenses for Johnson & Johnson in biotechnology, pharmaceuticals, vision care, diagnostics and other high technology areas of health care. Before joining Johnson & Johnson in 1980, Mr. Werner was Senior Vice President of Robert S. First, Inc., and was responsible for managing its European and, later, US health care management consulting business. Mr. Werner received his BS (high honors) and MS degrees from Princeton University and an MBA from the Harvard Graduate School of Business Administration.

Gunther Winkler, PhD, *Founder & CEO, BioMetheus LLC*

Dr. Winkler is a seasoned biotech executive and entrepreneur. He started his industry career at Biogen Idec where he held senior positions in R&D and in Corporate Administration including Head of Global Clinical Operations, VP of Strategic Initiatives and Senior VP, Asia Pacific. Dr. Winkler left Biogen Idec in 2011 and pursued his own entrepreneurial ventures. His current position is CEO of Biometheus LLC, which specializes in the discovery, acquisition and licensing of breakthrough technologies that are applicable to accelerating new drug development and reducing the associated cost.

Vincent Xiang, *Managing Director and VP of International Investments and BD at Humanwell Healthcare Group*

Vincent Xiang is Managing Director and VP of International Investments and BD at Humanwell Healthcare Group, a Chinese life sciences company with $3B market cap and $1.2B/year revenue. Vincent worked as Managing Director of Burrill China. From 2004 - 2011, he was VP and Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Prior to that, Vincent played various roles in bridging life sciences (SinoPharm, Genyous and LDX) and finance (Acacia Research and BioAdvance) between the East and the West.

Vincent received his PhD in molecular biology (USB), MBA (Wharton), and BS (Fudan). He is a founding member of BayHelix Group.

Alan Z.Y. Yan, *President & Chief Executive Officer, Beijing Synercare Pharma Tech Co., Ltd*

Alan Yan co-founded Beijing Synercare Pharma Tech Co., Ltd in late 2013, and he is President & CEO of the company. Alan received his medical degree in Shanghai Medical University in 1993. After joining the pharmaceutical industry 20 years ago, Alan worked in the Chinese affiliates of Glaxo, Amgen and Roche in the field of clinical development and strategic marketing. Since 2001, Alan has been a senior executive in the Chinese affiliate of Merck KGaA, Sandoz and Actelion. His management scope has covered clinical & regulatory development, portfolio & strategy, business development, sales and marketing, as well as commercial channel management. In the last 4+ years before he co-founded Synercare, Alan was General Manager of Actelion China.

Speaker Bios

Cissy S. Young, Ph.D. MBA, *Executive Director, Life Sciences Practice, Russell Reynolds Associates*

Dr. Cissy S. Young is a member of the firm's Healthcare sector. Based in Boston, Cissy focuses on addressing leadership and management needs for clients in the healthcare industry, including pharmaceutical, biotechnology, medical device, diagnostic, and healthcare services organizations.

Previous Experience

Cissy has over a decade of early-stage technology licensing and venture-backed biotech operating experience. Prior to joining Russell Reynolds Associates, Cissy was Director of Strategy and Business Development at Cerulean Pharma Inc., a privately-held, venture-backed biopharmaceutical company developing a novel class of anticancer agents. As a member of the management team, Cissy was a major contributor to building the company from its early days by advancing partnership opportunities and product development strategies. She was responsible for business development, competitive intelligence, corporate communications, business and financial analysis, deal structure and negotiation, and alliance management.

Prior to Cerulean, she was Director of Business Development and a member of the management team at TetraLogic Pharmaceuticals, also a venture-backed oncology therapeutics company. In sum, Cissy had been part of two successful management teams that raised over $100 million in venture capital for advancing early-stage discoveries into the clinic. Cissy began her business career as a Technology Licensing Officer, responsible for technology licensing and new company formation for The Pennsylvania State University. Earlier in her scientific career, Cissy focused her research on signal transduction pathways in cancer cells.

Additional Professional Activities

Cissy is a member of the Board of Directors of Community Rowing Inc. (CRI), one of the largest rowing clubs in the United States, advancing the mission of "Rowing For All". She serves on the Development Committee, co-chairs the Annual Fund, and spends the pre-dawn hours rowing on the Charles River. Cissy is also an active member of the Healthcare Business Women's Association (HBA) and serves as a mentor in the Boston Chapter Mentoring Program.

Debra Yu, MD, *Managing Director, Labrador Advisors*

Debra is Managing Director of Labrador Advisors, a life sciences advisory firm that works with companies on corporate development, business development, and strategy. A significant portion of her time now is devoted to China-directed cross border partnering. Previously, Debra was Head of Strategy at WuxiApptec. She co-founded and co-led Pfizer's Venture capital group and served as a senior member of Pfizer's worldwide business development team. She was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two prominent bay area VC firms. She has an MD from Harvard and a BA in Molecular biology from Princeton. She is the Midatlantic Regional Chairperson for Bayhelix, a Governor of the Asian American Alumni Association of Princeton and is a member of the Biology Council, Institute for Advanced Studies in Princeton, NJ. She also serves on the board of a non-profit called The Center for Supportive Schools.

Peony Yu, MD, *Vice President, Clinical Development, FibroGen, Inc.*

Dr. Yu brings to FibroGen expertise in the design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the US and EU, as well as experience with successful leadership of clinical teams.

Dr. Yu was most recently Vice President, Clinical Research, at Anesiva, Inc. where she was responsible for management of clinical research, statistics / data management, clinical operations, and medical affairs / medical information for all clinical programs, including the late-stage clinical development and approval of Zingo™, a drug-device combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development, at ALZA Corporation (a subsidiary of Johnson & Johnson) where she was Global Clinical Lead for IONSYS, a drug-device combination for post-operative pain, and led a successful New Drug Application resubmission with the U.S. Food & Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc., and at Elan Pharmaceuticals.

Dr. Yu received a BS in Chemical Engineering and an MD both from the University of California, Davis, followed by residency training at Stanford Medical School.

Speaker Bios

Wei Zhang, *Head of Corporate Development, GoodStart Genetics*

Wei is currently leading business development activities at Good Start Genetics, a next generation molecular diagnostics company. Previously, Wei was at Safeguard Scientifics, a public venture capital fund, where he led healthcare investments including Good Start Genetics. Prior to Safeguard, Wei worked at BioAdvance, a Pennsylvania state initiative committed to funding early-stage life sciences companies. Wei has also interned at or consulted for several venture capital firms in the US and Asia. In his early career, Wei worked in the biotech industry developing biologics in various therapeutic areas. Wei holds a BS from Nanjing University in China, a PhD in chemistry from Boston University, and an MBA from the Wharton School at University of Pennsylvania. Wei also completed the prestigious Kauffman Fellows Program dedicated to innovation investing.